20
Apr

A novel immuno-oncology treatment from Novartis and the University of Pennsylvania came through in an early safety study on patients with solid tumors, encouraging investigators and burnishing its potential.

…read more

Source: Novartis’ new CAR-T hopeful looks safe in an early solid tumor study

    

0 No comments